相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism
Maria Cristina Vedovati et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up
Trine-Lise Larsen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Irbaz Bin Riaz et al.
MAYO CLINIC PROCEEDINGS (2022)
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score
Maria A. de Winter et al.
THROMBOSIS AND HAEMOSTASIS (2022)
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer
Giancarlo Agnelli et al.
THROMBOSIS AND HAEMOSTASIS (2022)
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study
Walter Ageno et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
Floris T. M. Bosch et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE
Jeffrey Weitz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism
Damon E. Houghton et al.
MAYO CLINIC PROCEEDINGS (2021)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
Frits Mulder et al.
BLOOD (2020)
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis
Michela Giustozzi et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Trine-Lise Hannevik et al.
THROMBOSIS RESEARCH (2020)
Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome
Nuria Vicente-Ibarra et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study
Frederikus A. Klok et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study
Noemie Kraaijpoel et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
S. Kaatz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Long-Term Survival in a Large Cohort of Patients with Venous Thrombosis: Incidence and Predictors
Linda E. Flinterman et al.
PLOS MEDICINE (2012)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism.: Findings from the RIETE Registry
Nuria Ruiz-Gimenez et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Cancer and thrombosis: from molecular mechanisms to clinical presentations
H. R. Buller et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Incidence and mortality of venous thrombosis:: a population-based study
I. A. Naess et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation
MC Fang et al.
ANNALS OF INTERNAL MEDICINE (2004)
Mucosal damage: A major risk factor for severe complications after cytotoxic therapy
DE Peterson et al.
SEMINARS IN ONCOLOGY (2004)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study
JA Heit et al.
ARCHIVES OF INTERNAL MEDICINE (2000)